Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47 - Smolen, Josef S; Trefler, Jakub; Racewicz, Artur; Jaworski, Janusz; Zielińska, Agnieszka; Krogulec, Marek; Jeka, Sławomir; Wojciechowski, Rafał; Kolossa, Katarzyna; Dudek, Anna; Krajewska-Włodarczyk, Magdalena; Hrycaj, Paweł; et al. (Rheumatic & musculoskeletal diseases open, 2024)
Keywords: Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; arthritis, rheumatoid; Arthritis, Rheumatoid - drug therapy; autoimmune diseases; Biological products; biosimilar pharmaceuticals; Biosimilar Pharmaceuticals - administration & dosage; Biosimilar Pharmaceuticals - adverse effects; Biosimilar Pharmaceuticals - therapeutic use; Cytokines; Double-Blind Method; Drug dosages; FDA approval; Female; Humans; Licenses; Male; Middle Aged; Monoclonal antibodies; Original Research; Patients; Pharmacokinetics; Regulatory approval; Remission (Medicine); Rheumatoid Arthritis; Rheumatology; Severity of Illness Index; Therapeutic Equivalency; Treatment Outcome; Vein & artery diseases; United States--US; autoimmune diseases; biosimilar pharmaceuticals; arthritis, rheumatoid